Aims To investigate the impact of the specific red blood cell binding on the pharmacokinetics and pharmacodynamics of the nucleoside transport inhibitor draflazine after i.v. administration at various infusion rates. It was also aimed to relate the red blood cell (RBC) occupancy of draflazine to the ex vivo measured adenosine breakdown inhibition (ABI). Methods Draflazine was administered to healthy volunteers as a 15-min i.v. infusion of 0.25, 0.5, 1, 1.5 and 2.5 mg immediately followed by an infusion of the same dose over 1 h. Plasma and whole blood concentrations were measured up to 120 h post dose, and were related to the ex vivo measured ABI, serving as a pharmacodynamic endpoint. The capacity-limited specific binding of draflazine to the nucleoside transporter located on the erythrocytes was evaluated by a population approach. Results The estimate of the population parameter typical value (%CV) of the binding constant K d and the maximal specific binding capacity (B max ) was 0.385 (3.5) ng ml −1 plasma and 158 (2.1) ng ml −1 RBC, respectively. The non-specific binding was low. The specific binding to the erythrocytes was a source of non-linearity in the pharmacokinetics of draflazine. The total plasma clearance of draflazine slightly decreased with increasing doses, whereas the total clearance in whole blood increased with increasing doses. The sigmoidal E max equation was used to relate the plasma and whole blood concentration of draflazine to the ex vivo determined ABI. In plasma, typical values (%CV) of E max , IC 50 and Hill factor were 81.4 (1.9)%, 3.76 (9.3) ng ml −1 and 1.06 (3.4), respectively. The relationship in whole blood was much steeper with population parameter typical values (%CV) of E max , IC 50 and Hill factor of 88.2 (2.0)%, 65.7 (2.8) ng ml −1 and 4.47 (5.5), respectively. The RBC occupancy of draflazine did not coincide with the ex vivo measured ABI. The observed relationship between RBC occupancy and ABI was not directly proportional but similar for all studied infusion schemes. Conclusions The findings of this study show that the occupancy of the nucleoside transporter by draflazine should be at least 90% in order to inhibit substantially adenosine breakdown in vivo. On the basis of these findings it is suggested that a 15 min infusion of 1 mg draflazine followed by an infusion of 1 mg h −1 could be appropriate in patients undergoing a coronary artery bypass grafting.
Introduction rapidly catabolised, so that the cardioprotective effect is fairly transient [7] [8] . Endogenous adenosine is released in the intercellular interstitial space of cardiac tissue in response to any negative An important role in the fate of adenosine is played by the nucleoside transporter which facilitates the intracellular balance between energy supply and energy demand [1, 2] . The multitude of pharmacological properties of the nucleouptake of adenosine. Nucleoside transporters are located on the endothelial cells lining the vasculature as well as on red side adenosine may limit myocardial damage from ischaemia blood cells [9, 10] . Inhibition of the nucleoside transporter Consequently, the presence of extracellular adenosine will blood biochemistry, haematology and urinalysis testing within 2 weeks prior to the start of the study. The subject be prolonged so that it may reach concentrations sufficiently high to exert cardioprotective effects. characteristics are given in Table 1 . The use of all medication, with the exception of Draflazine is a nucleoside transport inhibitor with cardioprotective effects in various in vitro and in vivo models for paracetamol, had to be stopped at least 14 days prior to the start of the study. Paracetamol was permitted up to 3 days cardioprotection [11] [12] [13] [14] [15] [16] [17] . One of the possible indications for draflazine is cardiac protection during cardiac surgery before the start of each study session. such as coronary artery bypass grafting (CABG). In the firsttime-to-man study of draflazine, a 15 min i.v. infusion of 2.5 mg draflazine was administered to healthy male subjects Study design [18] . This study showed that the red blood cell/plasma distribution of draflazine was concentration dependent and
The study was conducted according to the principles of the Declaration of Helsinki and its subsequent revisions. The could be characterized on the basis of a specific binding to the nucleoside transporter on the red blood cells [19, 20] .
approval of the study was obtained from a recognised Ethics Committee. This capacity-limited specific binding appeared to be a source of non-linearity in the pharmacokinetics of draflazine.
This randomized double-blind placebo-controlled doseescalation study consisted of separate study sessions. Before Therefore, the present study in healthy subjects was conducted to investigate further the impact of the specific the start of each study session, subjects had fasted overnight and the intake of alcoholic beverages, coffee, tea, cola, red blood cell binding on the pharmacokinetics and pharmacodynamics of draflazine after i.v. administration at chocolate or any other product containing caffeine or cocoa was forbidden from 24 h before till the end of each session. various infusion rates. The population average specific binding parameters of draflazine and the inter-and intraindivIn five study sessions, two alternating groups of 12 subjects received a 15 min i.v. infusion of 0.25, 0.5, 1, 1.5 idual variability of this red blood cell binding were determined by a non-linear mixed effect method and 2.5 mg draflazine immediately followed by the same dose over 1 h. The i.v. solutions of draflazine or placebo (NONMEM). In addition, the population pharmacokineticdynamic parameters of the ABI-draflazine concentration were infused in a forearm vein by means of an infusion pump. Subjects remained in supine position from the start relationship as well as the inter-and intraindividual variability of these parameters were also determined by a population of the intravenous infusion until 60 min after the end of the 1 h infusion. approach (NONMEM).
In a previous study it was suggested that the red blood Within each study session, eight subjects received an infusion of draflazine and the other four subjects received cell nucleoside transporter occupancy of draflazine (RBC occupancy) could serve as a useful pharmacodynamic placebo. The clinical investigator was only aware of the administered dose of draflazine in each session. endpoint for future dose ranging studies [18] . Therefore, in the present study, the RBC occupancy of draflazine was Venous blood was collected from an arm vein immediately prior to and at specific time points after the start of the evaluated for various infusion rates of draflazine and was related to the ex vivo measured adenosine breakdown infusion up to 120 h post-infusion. Per subject, a total number of 15 blood samples were taken in each study inhibition (ABI).
session. Blood samples during the first day were taken from the arm opposite to the infusion arm. A 7.5 ml blood sample Methods was divided over two heparinized tubes. One 2.5 ml blood sample was stored at −20°C until assayed for draflazine.
Subjects
Plasma from the other 5 ml blood sample was harvested and was stored at −20°C until the time of drug assay. At the The subjects participated in this study after having given their voluntary written informed consent. All subjects were times of blood sampling for the determination of the drug concentration, additional 4 ml blood samples were collected male Caucasians between the ages of 18 and 55 years with a body weight within 20% of the ideal weight as described on acid citrate dextrose (ACD) for the ex vivo determination of the adenosine breakdown inhibition. These samples were in the Metropolitan Life Insurance Company's Height and Weight Table. All were in good health as established by stored at 4°C and were kept on ice during the weekly transport to the site of analysis. Previous data have shown medical history, physical examination, ECG and results of [172] [173] [174] [175] [176] [177] [178] [179] [180] [181] [182] [183] [184] [185] [186] [187] [188] [189] [190] [191] that no change in the ex vivo breakdown of adenosine was of subject j . C RBCij served as a dependent variable of the population RBC/plasma distribution model, and was used observed up to a storage period of 12 days at 4°C.
for the subsequent estimation of the erythrocyte binding parameters (equation 3).
Drug concentrations
As draflazine exhibits a capacity-limited high-affinity Concentrations of draflazine in whole blood were deterbinding to the transporters located on the red blood cells mined by reversed phase high-performance liquid chroma- [18, 20] , the total red blood cell concentration of draflazine tography with u.v. detection at 254 nm [21] . The limit of was related to the plasma concentration as: quantification was 5 ng ml −1 . The accuracy (RE) and precision (CV) obtained from independently prepared quality Ĉ RBCij = B maxj ΩC pij K dj +C pij +K non-specificj ΩC pij (3) control samples was respectively +6.6% and 6.5% at 16.2 ng ml −1 (n=22), +1.1% and 3.8% at 101 ng ml
where Ĉ RBCij is the model-predicted ith total red blood cell (n=21) and −1.4% and 4.5% at 486 ng ml −1 (n=21).
concentration of draflazine in the jth individual at the Plasma concentrations of draflazine were determined by measured plasma concentration C pij . The measured C pij a red blood cell binding assay after selective extraction [22] .
served as the independent variable of the population RBC/ The limit of quantification was 0.10 ng ml −1 plasma. The plasma model. B maxj is the Bayesian estimate of the maximal RE and CV obtained from independently prepared quality concentration of draflazine specifically bound to erythrocytes control samples was respectively −3.0% and 15.8% at in the jth individual. K dj is the predicted dissociation 0.114 ng ml −1 (n=6), +6.2% and 9.7% at 0.510 ng ml
constant in subject j , defined as the draflazine plasma (n=6) and −1.8% and 9.9% at 3.32 ng ml −1 (n=6).
concentration at which 50% of B maxj is specifically bound to the red blood cells. Finally, K non-specificj is the Bayesian Ex vivo assessment of adenosine breakdown inhibition (ABI) estimate of the constant expressing the non-specific erythrocyte binding in the jth volunteer. Blood samples on ACD were centrifuged and an erythrocyte Based on the Bayesian estimates of the specific binding suspension was made. Then, adenosine was added to a final parameters in each individual subject, the percentage red concentration of 40 mm. Samples were centrifuged after blood cell nucleoside transporters occupied by draflazine being incubated for 20 min at 25°C. The pellet was (RBC occupancy ij ) was calculated for each measured plasma discarded and the final clear supernatant was stored at concentration (C pij ) as: −20°C until assayed for adenosine, inosine and hypoxanthine. This method was described in more detail by Wainwright et al. [23] and Van Belle et al. [14] .
RBC occupancy ij (%)= C RBC,specificij B max j Ω100
Total concentrations of adenosine, inosine and hypoxanthine in the final supernatant were measured using h.p.l.c. as described previously [24, 25] . Then, the adenosine
concentration (f ADO ) was calculated as the fraction of the sum of the concentrations of adenosine, hypoxanthine and inosine. The adenosine breakdown inhibition (ABI) was expressed as a percentage and was calculated as:
Pharmacokinetic analysis
The capacity-limited binding of draflazine to the red blood cells appeared to be a source of non linearity in the where ABI ij is the percentage inhibition of the breakdown pharmacokinetics of the drug in plasma as well as in whole of adenosine in sample i of subject j . f ADO0j and f ADOij blood [18] . Therefore, a compartmental model could not represent the fraction of adenosine in the jth individual as be used to describe the plasma and blood concentrationdetermined in the sample taken just before and in the ith time profiles of draflazine after different infusion schemes. sample after the start of the draflazine infusion, respectively.
Non-compartmental pharmacokinetic parameters were determined based on the individual plasma and blood concentration-time curves using the actual sampling times.
Population RBC/plasma distribution model
The initial half-life post-infusion (t 1/2,post-infusion ) and the For each individual subject, the total red blood cell terminal half-life (t 1/2,z ) were determined by linear regression concentration of draflazine was calculated from the measured of the post-infusion and terminal points of the log-linear whole blood and plasma concentration of draflazine as:
concentration-time curves, respectively. The total plasma and blood clearance of draflazine was calculated by dividing
the infused dose by the total AUC.
where C bij and C pij are respectively the whole blood Population concentration-effect relationship model concentration and the plasma concentration of draflazine measured in sample i of individual j and H j is the measured
The sigmoidal E max or Hill equation was used to relate the measured plasma and whole blood concentrations of each haematocrit of the jth subject. C RBCij is the calculated total red blood cell concentration of draflazine in the ith sample individual subject to the ex vivo measured adenosine The following general model with a proportional and an breakdown inhibition in individual j at the measured additional error term was assumed for the remaining concentration C ij . The measured plasma or whole blood unexplained intraindividual variability: concentration of draflazine (C ij ) served as the independent variable of the population concentration-effect relationship
Ωe RBCij model. Ê maxj is the Bayesian estimate of the maximal percentage adenosine breakdown inhibition in the jth subject. The parameter IĈ 50j represents the predicted (9) concentration of draflazine in the jth individual that produces where C RBCij is the ith total red blood cell concentration 50% of the maximal adenosine breakdown inhibition; and in the jth individual, and Ĉ RBCij is the corresponding ĉ j is the Bayesian estimate of the factor describing the predicted concentration from equation 3. The variables steepness of the sigmoidal E max relationship in the subject j .
h RBC1 and h RBC2 are proportional and additional error terms, Separate independent sigmoidal E max population models respectively. Finally, e RBCij denotes the residual intrasubject were constructed for the measured ABI related to the random error distributed normally with zero mean and measured plasma concentration of draflazine and for the unit variance. ABI related to the whole blood concentration of draflazine. 
Concentration-effect relationship model.
In preliminary analyses, a similar parameter g c j was included in the model to account for the interindividual ln K non-specificj =ln K non-specific +g Knon-specific j (8) variability (12) where ABI ij is the ith adenosine breakdown inhibition in Results the jth individual, and AB I ij is the corresponding predicted ABI from equation 5. h ABI1 and h ABI2 are proportional and Figure 1 depicts the calculated and predicted red blood cell concentrations of draflazine as a function of the plasma additional error terms, respectively. Finally, e ABIij denotes Figure 1 revealed that the RBC/plasma distribution of draflazine in each individual subject could be described by the capacity-limited specific binding and non-specific binding of draflazine to the red blood cells. In addition, the variability among subjects was small, which was further demonstrated by NONMEM parameter estimates of the inter-and intraindividual variability ( Table 2 ). The estimate of the population parameter typical value (%CV) of the maximal specific binding capacity B max , the dissociation constant K d and the non-specific binding constant K non-specific was 158 (2.1) ng ml Table 3 . After cessation of the 1 h infusions, plasma concentrations of draflazine decayed biphasically. Initial post-peak plasma concentrations of draflazine declined very rapidly ( Figure 2) . As a consequence, plasma concentrations following the two lowest doses of draflazine were only detectable up to 6-24 h post-infusion so that no terminal half-lives could be calculated (Table 3) . The mean initial half-life post-infusion (t 1/2post-infusion ) was 0.6-0.9 h and the terminal half-life (t 1/2,z ) averaged 18-20 h. The total plasma clearance of draflazine decreased with increasing doses (Table 3) . After cessation of the 1 h infusions, the biphasic decline of the concentration of draflazine in blood was much slower compared to that in plasma and the mean t 1/2,z of draflazine in blood was 35-48 h ( Table 3 ). The total blood clearance of draflazine increased with increasing doses and was much lower compared to that in plasma.
The NONMEM parameter typical values and the parameters expressing the inter-and intra-individual variability of the sigmoidal E max model relating the plasma and blood concentrations of draflazine with the ex vivo measured ABI are given in Table 4 . The correlation between the parameters of the sigmoidal E max model was negligible. The ABI as a function of the plasma and blood concentration of draflazine for each individual are depicted in Figure 3 . (Table 4 ). In addition, the sigmoidal E max relationship was much steeper in blood compared to that in plasma as demonstrated by the population typical value (%CV) for the Hill factor c of 1.06 (3.4) and 4.47 (5.5) in plasma and blood respectively. calculated RBC occupancy of draflazine are plotted as a Table 4 NONMEM parameter estimates of the sigmoidal E max model relating the ex vivo measured adenosine breakdown inhibition (ABI) to the concentration of draflazine in plasma and whole blood. and 98.7%, respectively. Figure 5 depicts the mean ABI as a function of the mean RBC occupancy of draflazine. It is clear that no 151 relationship was present between both endpoints. Figure 5 further shows that the relationship between the ABI and the RBC occupancy was similar for all infusion schemes of draflazine.
Discussion
The typical value for K d shows that 50% of all nucleoside transporters are occupied by draflazine at a plasma concentration of 0.385 ng ml the nucleoside transporters located on the red blood cells was confirmed in vivo by Snoeck et al. [18] . We previously reported a more than two-fold higher in vivo K d of function of time in Figure 4 . The ABI-time profiles were different from the RBC occupancy-time profiles. A small 0.87 ng ml −1 plasma (1.45 nmol l −1 ), which was still in the range of the individual Bayesian estimates of the present ABI was measured during the 15 min infusion of 0.25 mg followed by the same dose over 1 h (Figure 4a ). For 1, 1.5 population analysis. This K d was based on the pooled plasma and mean blood concentrations of eight subjects after a and 2.5 mg, the ABI was maximal at the end of the 15 min infusion and decreased during the subsequent 1 h infusion.
single 15 min i.v. infusion of 2.5 mg draflazine. The present typical value of K d was very accurately estimated by The mean ABI at the end of the 15 min infusion of 0.5, 1, 1.5 and 2.5 mg was 45.7%, 63.6%, 67.7% and 84.5%, NONMEM (CV 3.5%) and most likely approaches more closely the 'real' dissociation constant as the whole range of respectively. At the end of the 1 h infusions of 0.5 mg h −1 , 1 mg h −1 , 1.5 mg h −1 and 2.5 mg h −1 , the ABI averaged the C RBC −C p relationship was covered in this study. In addition, more subjects and more infusion schemes were 54.2%, 56.1%, 59.7% and 74.7%, respectively. Figure 4b shows that the RBC occupancy further increased during the used for the population estimate. Finally, the interindividual variability in K d of the healthy subjects was low (CV 13.1%) 1 h infusions of 0.25 and 0.5 mg h , whereas the occupancy at the end of the 15 min infusion of 1, 1.5 and 2.5 mg was and was accurately estimated (CV 8.9%).
The typical value of the B max of the specific binding of The present population estimate of IC 50 of 3.76 ng ml −1 most likely approaches more closely the 'real' IC 50 in plasma draflazine to the nucleoside transporters located on the erythrocytes was 158 ng ml −1 RBC, and was very precisely as the whole range of the ABI-C p relationship was covered in this study. estimated by NONMEM (CV 2.1%). The population B max was similar to the previously found value of 164 ng ml
The ex vivo measured ABI was a useful pharmacodynamic endpoint as the measured inhibition of the overall breakdown RBC [18] . In addition, as 11 of human blood contains 5×10 12 erythrocytes, it can be calculated from B max and of adenosine possibly leads to a prolongation of the pharmacological effects of adenosine. The RBC occupancy the molecular weight of draflazine (604.53) that each erythrocyte has about 14000 nucleoside transporters, which did not coincide with the measured ex vivo ABI ( Figure 5 ). However, the observed relationship was similar for all is in agreement with the previously reported in vitro binding data [19, [28] [29] [30] . The typical magnitude of the non-specific infusion schemes. Figure 5 depicts that the erythrocytes have to be occupied for 90% or more in order to obtain a binding constant K non-specific was 0.615, demonstrating that the non-specific binding was about 0.3% of the total binding substantial inhibition of the breakdown of adenosine. This can easily be explained by the huge preponderance of at K d and about 23% at 80 ng ml −1 plasma. The nonspecific binding constant was almost two-fold higher than transport capacity vs enzymatic breakdown capacity. It is only at a relatively high RBC occupancy of draflazine that that found in the previous study [18] . From equation 3 it is clear that, for a similar C RBC −C p relationship, a lower the nucleoside transport process rather than the enzymatic breakdown becomes the rate limiting step for the overall population estimate of K d will result in a higher typical value of the non-specific binding constant.
breakdown of adenosine. The overall catabolism of adenosine is the result of an initial transport of adenosine into the The intra-individual or unexplained variability was well described by the population parameters expressing the erythrocytes followed by deamination of adenosine by adenosine deaminase producing inosine, and finally a proportional and additive error of the model. These population parameters indicate that the intra-individual breakdown of inosine to hypoxanthine by purine nucleoside phosphorylase. The nucleoside transporter as well as the variability was low in this uniform group of healthy subjects (Table 2) . However, the non-linear red blood cell partitionenzymes do have their own specific kinetic parameters making the kinetics of the overall breakdown of adenosine ing of draflazine in the more diverse group of patients undergoing a CABG may be different and may be influenced relatively complicated. Previously, Van Belle et al. [14] demonstrated that a by the disease status of the patient.
The specific binding to the erythrocytes appeared to be a substantial inhibition of the breakdown of adenosine by draflazine largely prevented cardiac damage and death in source of non-linearity in the pharmacokinetics of draflazine. The total plasma clearance of draflazine slightly decreased catecholamine challenged rabbits. To obtain a substantial ABI in CABG patients, the RBC occupancy should be as with increasing doses, whereas the total clearance in whole blood increased with increasing doses (Table 3) . The high as possible. However, a complete occupancy should be avoided as this may lead to systemic accumulation of pharmacokinetics of draflazine in plasma and whole blood were not predictable from the pharmacokinetic data obtained adenosine and possibly resulting in unwanted side-effects [18] . For these reasons, a 15 min i.v. infusion of 1 mg in the previous study. Moreover, within this study, the disposition of draflazine following a certain infusion scheme immediately followed by an infusion of 1 mg h −1 could be justified as the appropriate infusion scheme. An infusion rate could not be extrapolated from the data of the other infusion schemes. The impact of the specific erythrocyte binding on of 1.5 or 2.5 mg h −1 could possibly result in a systemic accumulation of adenosine in some patients, making the the pharmacokinetics of draflazine could be further explored by a model that integrates both pharmacokinetic and binding favoured therapeutic window relatively small. Moreover, as the RBC occupancy rapidly declined after cessation of the phenomena. An additional study with longer infusion durations of draflazine will allow to further develop this 1 h infusion, it is expected that draflazine has to be infused during the whole period of risk in order to have the optimal pharmacokinetic binding model and to investigate the steady-state pharmacokinetics of the drug.
anti-ischaemic protection. Studies with longer infusion durations will be needed to further investigate the RBC For each individual subject, the relationship between the ex vivo measured ABI and the concentration of draflazine in occupancy and the individual variability in the RBC occupancy during and after these long infusions, so that the plasma and whole blood could be characterized on the basis of a sigmoidal E max model equation (Figure 3) . The dose rationale can be further founded. We conclude that the specific binding of draflazine to the difference in IC 50 and c between the draflazine plasma-and blood-% ABI relationship might also be explained by the nucleoside transporters located on the erythrocytes was a source of non-linearity in the pharmacokinetics of draflazine. non-linear red blood cell partitioning. Typical values of E max , IC 50 and c in whole blood were very precisely
The estimate of the population parameter typical value of the specific binding constant K d was 0.385 ng ml −1 plasma estimated by NONMEM (Table 4 ). In plasma, the precision of the IC 50 was somewhat larger (9.3%), which could be (0.64 nmol l −1 ), demonstrating the high affinity of this binding. The percentage of red blood cell nucleoside explained by a larger interindividual variability (45.1%). With the exception of the IC 50 in plasma, the parameters transporters occupied by draflazine should be at least 90% in order to substantially inhibit adenosine breakdown in of the sigmoidal E max equation in plasma and whole blood were similar to the previously reported values [18] . The vivo. Finally, based on the percentage red blood cell occupancy of draflazine, it is suggested that a 15 min i.v. typical value of the IC 50 in plasma was about three-fold lower than the previously reported IC 50 of 10.5 ng ml −1 . infusion of 1 mg draflazine immediately followed by an effects of nucleoside transport inhibition in rabbit hearts. Ann infusion of 1 mg h −1 could be justified in patients under- 
